Published in Pharma Investments, Ventures and Law Weekly, December 6th, 2009
"Today's Merck has a robust portfolio and pipeline of cardiovascular medicines for conditions ranging from heart disease to metabolic syndrome. More than ever, our new company is committed to improving patient outcomes and providing comprehensive solutions to prevent and treat heart disease," said Peter S. Kim, Ph.D., president, Merck Research Laboratories. "We're confident more can be done through science and education to save and improve the lives of people suffering...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly